Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers
Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody...
Gespeichert in:
| Veröffentlicht in: | Experimental and therapeutic medicine 2021-06, Vol.21 (6), p.605-605, Article 605 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 605 |
|---|---|
| container_issue | 6 |
| container_start_page | 605 |
| container_title | Experimental and therapeutic medicine |
| container_volume | 21 |
| creator | Săftescu, Sorin Negru, Șerban Volovăț, Simona Popovici, Dorel Chercota, Vlad Stanca, Simona Feier, Horea Malita, Daniel Dragomir, Radu Volovăț, Constantin |
| description | Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody, is the first immune checkpoint inhibitor approved by the US Food and Drug Administration in 2014 for cases of metastatic melanoma and in 2015 for cases of squamous cell lung cancer and kidney cell cancer. The present study aimed to identify predictive markers (favorable or unfavorable) for time to treatment discontinuation using nivolumab in the second or subsequent line of therapy of metastatic NSCLC cases. Analysis of a group of 78 NSCLC patients treated with nivolumab allowed the identification of negative predictive markers, related to the presence of metastases (adrenal in men under 65 years, liver, brain and the number of metastatic sites) and the hematological profile (neutrophilia at the initiation of treatment and lymphocyte variation at 6 weeks of treatment). |
| doi_str_mv | 10.3892/etm.2021.10037 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8082661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A662836128</galeid><sourcerecordid>A662836128</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-2cac84b09bd7623629d9ba96a600738433901eab2269917885fc50d6b213dc6c3</originalsourceid><addsrcrecordid>eNptUk1r3DAQFaWlCdtceyyCXnrZrT5s2boUQugXBNpDexayPN4oWNJWkgO55pd3nG7TDyKBJGbePM0bHiEvOdvJXou3UMNOMMF3nDHZPSGnvNNiyxlvnx7fTPf8hJyVcs1wtYr3ffucnEippRJKnJK7rxlG72rKhaaJ1iugGcohxQK0Jhr9TZqXYAfqQ1hiwny2h1vq4z20gEtxpCnTsgwFfiwQK519hEInDAaotlRbvaMxxW0Jdp6pAzzmJe6ps9FBLi_Is8nOBc6O94Z8__D-28Wn7eWXj58vzi-3TnasboWzrm8GpoexUwLb16MerFZWMdbJvkFNjIMdhFBa8w6FTq5loxoEl6NTTm7Iu1-8h2UIMDrsNdvZHLIPNt-aZL35NxP9ldmnG9OzXijFkeDNkSAnlFqqCb6scmyEtBQjWsFbxoVsEPr6P-h1WnJEeSuq4Zw1nf6D2tsZjI9Twn_dSmrOlRK9VByPDdk9gsI9QvA4f5g8xh8rcDmVkmF60MiZWY1j0DhmNY65Nw4WvPp7Mg_w3zaRPwECYb8u</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2524110479</pqid></control><display><type>article</type><title>Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers</title><source>PubMed Central</source><creator>Săftescu, Sorin ; Negru, Șerban ; Volovăț, Simona ; Popovici, Dorel ; Chercota, Vlad ; Stanca, Simona ; Feier, Horea ; Malita, Daniel ; Dragomir, Radu ; Volovăț, Constantin</creator><creatorcontrib>Săftescu, Sorin ; Negru, Șerban ; Volovăț, Simona ; Popovici, Dorel ; Chercota, Vlad ; Stanca, Simona ; Feier, Horea ; Malita, Daniel ; Dragomir, Radu ; Volovăț, Constantin</creatorcontrib><description>Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody, is the first immune checkpoint inhibitor approved by the US Food and Drug Administration in 2014 for cases of metastatic melanoma and in 2015 for cases of squamous cell lung cancer and kidney cell cancer. The present study aimed to identify predictive markers (favorable or unfavorable) for time to treatment discontinuation using nivolumab in the second or subsequent line of therapy of metastatic NSCLC cases. Analysis of a group of 78 NSCLC patients treated with nivolumab allowed the identification of negative predictive markers, related to the presence of metastases (adrenal in men under 65 years, liver, brain and the number of metastatic sites) and the hematological profile (neutrophilia at the initiation of treatment and lymphocyte variation at 6 weeks of treatment).</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2021.10037</identifier><identifier>PMID: 33936262</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Age groups ; Anemia ; Body mass index ; Cancer therapies ; Creatinine ; Drug therapy ; FDA approval ; Females ; Gender differences ; Hematology ; Immunotherapy ; Lung cancer ; Lung cancer, Non-small cell ; Lymphocytes ; Males ; Metastasis ; Monoclonal antibodies ; Neutrophils ; Patient outcomes ; Prognosis ; Sarcopenia ; T cell receptors ; Targeted cancer therapy ; Topography ; Variables</subject><ispartof>Experimental and therapeutic medicine, 2021-06, Vol.21 (6), p.605-605, Article 605</ispartof><rights>Copyright: © Săftescu et al.</rights><rights>COPYRIGHT 2021 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2021</rights><rights>Copyright: © Săftescu et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082661/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082661/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33936262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Săftescu, Sorin</creatorcontrib><creatorcontrib>Negru, Șerban</creatorcontrib><creatorcontrib>Volovăț, Simona</creatorcontrib><creatorcontrib>Popovici, Dorel</creatorcontrib><creatorcontrib>Chercota, Vlad</creatorcontrib><creatorcontrib>Stanca, Simona</creatorcontrib><creatorcontrib>Feier, Horea</creatorcontrib><creatorcontrib>Malita, Daniel</creatorcontrib><creatorcontrib>Dragomir, Radu</creatorcontrib><creatorcontrib>Volovăț, Constantin</creatorcontrib><title>Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody, is the first immune checkpoint inhibitor approved by the US Food and Drug Administration in 2014 for cases of metastatic melanoma and in 2015 for cases of squamous cell lung cancer and kidney cell cancer. The present study aimed to identify predictive markers (favorable or unfavorable) for time to treatment discontinuation using nivolumab in the second or subsequent line of therapy of metastatic NSCLC cases. Analysis of a group of 78 NSCLC patients treated with nivolumab allowed the identification of negative predictive markers, related to the presence of metastases (adrenal in men under 65 years, liver, brain and the number of metastatic sites) and the hematological profile (neutrophilia at the initiation of treatment and lymphocyte variation at 6 weeks of treatment).</description><subject>Age groups</subject><subject>Anemia</subject><subject>Body mass index</subject><subject>Cancer therapies</subject><subject>Creatinine</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Females</subject><subject>Gender differences</subject><subject>Hematology</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lymphocytes</subject><subject>Males</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Neutrophils</subject><subject>Patient outcomes</subject><subject>Prognosis</subject><subject>Sarcopenia</subject><subject>T cell receptors</subject><subject>Targeted cancer therapy</subject><subject>Topography</subject><subject>Variables</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptUk1r3DAQFaWlCdtceyyCXnrZrT5s2boUQugXBNpDexayPN4oWNJWkgO55pd3nG7TDyKBJGbePM0bHiEvOdvJXou3UMNOMMF3nDHZPSGnvNNiyxlvnx7fTPf8hJyVcs1wtYr3ffucnEippRJKnJK7rxlG72rKhaaJ1iugGcohxQK0Jhr9TZqXYAfqQ1hiwny2h1vq4z20gEtxpCnTsgwFfiwQK519hEInDAaotlRbvaMxxW0Jdp6pAzzmJe6ps9FBLi_Is8nOBc6O94Z8__D-28Wn7eWXj58vzi-3TnasboWzrm8GpoexUwLb16MerFZWMdbJvkFNjIMdhFBa8w6FTq5loxoEl6NTTm7Iu1-8h2UIMDrsNdvZHLIPNt-aZL35NxP9ldmnG9OzXijFkeDNkSAnlFqqCb6scmyEtBQjWsFbxoVsEPr6P-h1WnJEeSuq4Zw1nf6D2tsZjI9Twn_dSmrOlRK9VByPDdk9gsI9QvA4f5g8xh8rcDmVkmF60MiZWY1j0DhmNY65Nw4WvPp7Mg_w3zaRPwECYb8u</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Săftescu, Sorin</creator><creator>Negru, Șerban</creator><creator>Volovăț, Simona</creator><creator>Popovici, Dorel</creator><creator>Chercota, Vlad</creator><creator>Stanca, Simona</creator><creator>Feier, Horea</creator><creator>Malita, Daniel</creator><creator>Dragomir, Radu</creator><creator>Volovăț, Constantin</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210601</creationdate><title>Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers</title><author>Săftescu, Sorin ; Negru, Șerban ; Volovăț, Simona ; Popovici, Dorel ; Chercota, Vlad ; Stanca, Simona ; Feier, Horea ; Malita, Daniel ; Dragomir, Radu ; Volovăț, Constantin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-2cac84b09bd7623629d9ba96a600738433901eab2269917885fc50d6b213dc6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age groups</topic><topic>Anemia</topic><topic>Body mass index</topic><topic>Cancer therapies</topic><topic>Creatinine</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Females</topic><topic>Gender differences</topic><topic>Hematology</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lymphocytes</topic><topic>Males</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Neutrophils</topic><topic>Patient outcomes</topic><topic>Prognosis</topic><topic>Sarcopenia</topic><topic>T cell receptors</topic><topic>Targeted cancer therapy</topic><topic>Topography</topic><topic>Variables</topic><toplevel>online_resources</toplevel><creatorcontrib>Săftescu, Sorin</creatorcontrib><creatorcontrib>Negru, Șerban</creatorcontrib><creatorcontrib>Volovăț, Simona</creatorcontrib><creatorcontrib>Popovici, Dorel</creatorcontrib><creatorcontrib>Chercota, Vlad</creatorcontrib><creatorcontrib>Stanca, Simona</creatorcontrib><creatorcontrib>Feier, Horea</creatorcontrib><creatorcontrib>Malita, Daniel</creatorcontrib><creatorcontrib>Dragomir, Radu</creatorcontrib><creatorcontrib>Volovăț, Constantin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Săftescu, Sorin</au><au>Negru, Șerban</au><au>Volovăț, Simona</au><au>Popovici, Dorel</au><au>Chercota, Vlad</au><au>Stanca, Simona</au><au>Feier, Horea</au><au>Malita, Daniel</au><au>Dragomir, Radu</au><au>Volovăț, Constantin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>21</volume><issue>6</issue><spage>605</spage><epage>605</epage><pages>605-605</pages><artnum>605</artnum><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody, is the first immune checkpoint inhibitor approved by the US Food and Drug Administration in 2014 for cases of metastatic melanoma and in 2015 for cases of squamous cell lung cancer and kidney cell cancer. The present study aimed to identify predictive markers (favorable or unfavorable) for time to treatment discontinuation using nivolumab in the second or subsequent line of therapy of metastatic NSCLC cases. Analysis of a group of 78 NSCLC patients treated with nivolumab allowed the identification of negative predictive markers, related to the presence of metastases (adrenal in men under 65 years, liver, brain and the number of metastatic sites) and the hematological profile (neutrophilia at the initiation of treatment and lymphocyte variation at 6 weeks of treatment).</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>33936262</pmid><doi>10.3892/etm.2021.10037</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-0981 |
| ispartof | Experimental and therapeutic medicine, 2021-06, Vol.21 (6), p.605-605, Article 605 |
| issn | 1792-0981 1792-1015 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8082661 |
| source | PubMed Central |
| subjects | Age groups Anemia Body mass index Cancer therapies Creatinine Drug therapy FDA approval Females Gender differences Hematology Immunotherapy Lung cancer Lung cancer, Non-small cell Lymphocytes Males Metastasis Monoclonal antibodies Neutrophils Patient outcomes Prognosis Sarcopenia T cell receptors Targeted cancer therapy Topography Variables |
| title | Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T11%3A04%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20the%20response%20to%20nivolumab%20immunotherapy%20in%20the%20second%20or%20subsequent%20lines%20for%20metastatic%20non-small%20cell%20lung%20cancers&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=S%C4%83ftescu,%20Sorin&rft.date=2021-06-01&rft.volume=21&rft.issue=6&rft.spage=605&rft.epage=605&rft.pages=605-605&rft.artnum=605&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2021.10037&rft_dat=%3Cgale_pubme%3EA662836128%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2524110479&rft_id=info:pmid/33936262&rft_galeid=A662836128&rfr_iscdi=true |